TY  - JOUR
T1  - LOw-molecular-weight heparins in the management of acute coronary syndromes
AU  - Zed PJ, Tisdale JE, Borzak S
Y1  - 1999/09/13
N1  - 10.1001/archinte.159.16.1849
JO  - Archives of Internal Medicine
SP  - 1849
EP  - 1857
VL  - 159
IS  - 16
N2  - Acute coronary syndromes (unstable angina and non–Q-wave myocardial infarction) are caused by the rupture of an atherosclerotic plaque, platelet activation, and fibrin deposition resulting in thrombosis. Aspirin and unfractionated heparin have traditionally been the treatments of choice for patients with acute coronary syndromes. Low-molecular-weight heparins offer potential advantages over unfractionated heparin, having proven equally effective for the treatment and prevention of many thromboembolic processes. Recently, a number of randomized controlled trials have been conducted to evaluate the role of low-molecular-weight heparins in the management of patients with unstable angina or non–Q-wave myocardial infarction. The purpose of this article is to review and evaluate the available literature on the use of low-molecular-weight heparins in the management of acute coronary syndromes to establish their role in therapy.
SN  - 0003-9926
M3  - doi: 10.1001/archinte.159.16.1849
UR  - http://dx.doi.org/10.1001/archinte.159.16.1849
ER  -